

# Stefano Rusconi

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/2574631/stefano-rusconi-publications-by-year.pdf>

**Version:** 2024-04-10

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

248 papers	4,746 citations	32 h-index	61 g-index
261 ext. papers	5,842 ext. citations	5.8 avg, IF	5.44 L-index

#	Paper	IF	Citations
248	Leronlimab (PRO 140) in vitro activity against 4-class drug resistant HIV-1 from heavily treatment experienced subjects.. <i>Pharmacological Research</i> , <b>2022</b> , 176, 106064	10.2	0
247	Hepatitis delta coinfection in persons with HIV: misdiagnosis and disease burden in Italy.. <i>Pathogens and Global Health</i> , <b>2022</b> , 1-9	3.1	0
246	Research news in clinical context.. <i>Sexually Transmitted Infections</i> , <b>2022</b> , 98, 237-238	2.8	
245	Has COVID-19 changed the approach to HIV diagnosis?. <i>Medicine (United States)</i> , <b>2021</b> , 100, e27418	1.8	0
244	Common, low-frequency, rare, and ultra-rare coding variants contribute to COVID-19 severity. <i>Human Genetics</i> , <b>2021</b> , 141, 147	6.3	3
243	Correlation between continuous Positive end-expiratory pressure (PEEP) values and occurrence of Pneumothorax and Pneumomediastinum in SARS-CoV2 patients during non-invasive ventilation with Helmet. <i>Sarcoidosis Vasculitis and Diffuse Lung Diseases</i> , <b>2021</b> , 38, e2021017	1.1	2
242	Has COVID-19 changed the approach to HIV diagnosis?: A multicentric Italian experience. <i>Medicine (United States)</i> , <b>2021</b> , 100, e27418	1.8	
241	PD-1 blockade counteracts post-COVID-19 immune abnormalities and stimulates the anti-SARS-CoV-2 immune response. <i>JCI Insight</i> , <b>2021</b> ,	9.9	7
240	Differences in the Prevalence of SARS-CoV-2 Infection and Access to Care between Italians and Non-Italians in a Social-Housing Neighbourhood of Milan, Italy. <i>International Journal of Environmental Research and Public Health</i> , <b>2021</b> , 18,	4.6	1
239	Accessibility to SARS-CoV-2 swab test during the Covid-19 pandemic: Did age make the difference?. <i>Health Policy</i> , <b>2021</b> , 125, 1580-1586	3.2	1
238	Research news in clinical context. <i>Sexually Transmitted Infections</i> , <b>2021</b> , 97, 476-477	2.8	
237	Association of Toll-like receptor 7 variants with life-threatening COVID-19 disease in males: findings from a nested case-control study. <i>ELife</i> , <b>2021</b> , 10,	8.9	51
236	Nucleoside Reverse-Transcriptase Inhibitor Resistance Mutations Predict Virological Failure in Human Immunodeficiency Virus-Positive Patients During Lamivudine Plus Dolutegravir Maintenance Therapy in Clinical Practice. <i>Open Forum Infectious Diseases</i> , <b>2021</b> , 8, ofab103	1	0
235	Acute and long-term disruption of glycometabolic control after SARS-CoV-2 infection. <i>Nature Metabolism</i> , <b>2021</b> , 3, 774-785	14.6	78
234	HIV and COVID-19 pandemic collision: turning challenges into opportunity. <i>Future Virology</i> , <b>2021</b> , 16, 311-313	2.4	1
233	Impact of switching to TAF/FTC/RPV, TAF/FTC/EVG/cobi and ABC/3TC/DTG on cardiovascular risk and lipid profile in people living with HIV: a retrospective cohort study. <i>BMC Infectious Diseases</i> , <b>2021</b> , 21, 595	4	1
232	Switching from boosted PIs to dolutegravir decreases soluble CD14 and adiponectin in high cardiovascular risk people living with HIV. <i>Journal of Antimicrobial Chemotherapy</i> , <b>2021</b> , 76, 2380-2393	5.1	2

231	Efficacy and durability of two- vs. three-drug integrase inhibitor-based regimens in virologically suppressed HIV-infected patients: Data from real-life ODOACRE cohort. <i>HIV Medicine</i> , <b>2021</b> , 22, 843-853 <sup>2.7</sup>	3
230	Early administration of lopinavir/ritonavir plus hydroxychloroquine does not alter the clinical course of SARS-CoV-2 infection: A retrospective cohort study. <i>Journal of Medical Virology</i> , <b>2021</b> , 93, 1421-1427 <sup>19.7</sup>	17
229	Overall Tolerability of Integrase Inhibitors in Clinical Practice: Results from a Multicenter Italian Cohort. <i>AIDS Research and Human Retroviruses</i> , <b>2021</b> , 37, 4-10	1.6 2
228	Enhancing care for people living with HIV: current and future monitoring approaches. <i>Expert Review of Anti-Infective Therapy</i> , <b>2021</b> , 19, 443-456	5.5 0
227	The Impact of the SARS-CoV-2 Outbreak on the Psychological Flexibility and Behaviour of Cancelling Medical Appointments of Italian Patients with Pre-Existing Medical Condition: The "ImpACT-COVID-19 for Patients" Multi-Centre Observational Study. <i>International Journal of Environmental Research and Public Health</i> , <b>2021</b> , 18,	4.6 4
226	Human-to-Cat SARS-CoV-2 Transmission: Case Report and Full-Genome Sequencing from an Infected Pet and Its Owner in Northern Italy. <i>Pathogens</i> , <b>2021</b> , 10,	4.5 19
225	Five Years With Dolutegravir Plus Lamivudine as a Switch Strategy: Much More Than a Positive Finding. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , <b>2021</b> , 88, 234-237	3.1 2
224	Durability of Dolutegravir-Based Regimens: A 5-Year Prospective Observational Study. <i>AIDS Patient Care and STDs</i> , <b>2021</b> , 35, 342-353	5.8 4
223	Rare variants in Toll-like receptor 7 results in functional impairment and downregulation of cytokine-mediated signaling in COVID-19 patients.. <i>Genes and Immunity</i> , <b>2021</b> ,	4.4 4
222	Compassionate remdesivir treatment of severe Covid-19 pneumonia in intensive care unit (ICU) and Non-ICU patients: Clinical outcome and differences in post-treatment hospitalisation status. <i>Pharmacological Research</i> , <b>2020</b> , 158, 104899	10.2 118
221	Effectiveness of Switching to Darunavir/Cobicistat in Virologically Suppressed HIV-Positive Patients Receiving Ritonavir-Boosted Protease Inhibitor-Based Regimen: The "STORE" Study. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , <b>2020</b> , 84, 290-294	3.1 0
220	The crosstalk between antiretrovirals pharmacology and HIV drug resistance. <i>Expert Review of Clinical Pharmacology</i> , <b>2020</b> , 13, 739-760	3.8 6
219	Shall We Dance? Extending TANGO® Results to Clinical Practice. <i>Clinical Infectious Diseases</i> , <b>2020</b> , 71, e200-e201	11.6 4
218	Self-reported Olfactory and Taste Disorders in Patients With Severe Acute Respiratory Coronavirus 2 Infection: A Cross-sectional Study. <i>Clinical Infectious Diseases</i> , <b>2020</b> , 71, 889-890	11.6 754
217	Genomic characterization and phylogenetic analysis of SARS-COV-2 in Italy. <i>Journal of Medical Virology</i> , <b>2020</b> , 92, 1637-1640	19.7 90
216	96-week results of a dual therapy with darunavir/ritonavir plus rilpivirine once a day triple therapy in patients with suppressed viraemia: virological success and non-HIV related morbidity evaluation. <i>HIV Research and Clinical Practice</i> , <b>2020</b> , 21, 34-43	1.7 4
215	CRISPR in HIV: dangers of CCR5 deletion. <i>Future Virology</i> , <b>2020</b> , 15, 207-209	2.4 1
214	Simplification to High Genetic Barrier 2-Drug Regimens in People Living With HIV Harboring 4-Class Resistance Enrolled in the PRESTIGIO Registry. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , <b>2020</b> , 84, e24-e28	3.1 1

213	Darunavir does not prevent SARS-CoV-2 infection in HIV patients. <i>Pharmacological Research</i> , <b>2020</b> , 157, 104826	10.2	40
212	Enhanced Immunological Recovery With Early Start of Antiretroviral Therapy During Acute or Early HIV Infection-Results of Italian Network of ACuTe HIV Infection (IN ACTION) Retrospective Study. <i>Pathogens and Immunity</i> , <b>2020</b> , 5, 8-33	4.9	5
211	Self-Reported Symptoms of SARS-CoV-2 Infection in a Nonhospitalized Population in Italy: Cross-Sectional Study of the EPICOV19 Web-Based Survey. <i>JMIR Public Health and Surveillance</i> , <b>2020</b> , 6, e21866	11.4	38
210	30-day mortality in patients hospitalized with COVID-19 during the first wave of the Italian epidemic: A prospective cohort study. <i>Pharmacological Research</i> , <b>2020</b> , 158, 104931	10.2	140
209	Overlooked cases of HIV infection: An Italian tale of missed diagnostic opportunities. <i>European Journal of Internal Medicine</i> , <b>2020</b> , 73, 30-35	3.9	6
208	Sitagliptin Treatment at the Time of Hospitalization Was Associated With Reduced Mortality in Patients With Type 2 Diabetes and COVID-19: A Multicenter, Case-Control, Retrospective, Observational Study. <i>Diabetes Care</i> , <b>2020</b> , 43, 2999-3006	14.6	133
207	Factors associated with hospital admission for COVID-19 in HIV patients. <i>Aids</i> , <b>2020</b> , 34, 1983-1985	3.5	16
206	Circulating endothelial progenitors are increased in COVID-19 patients and correlate with SARS-CoV-2 RNA in severe cases. <i>Journal of Thrombosis and Haemostasis</i> , <b>2020</b> , 18, 2744-2750	15.4	23
205	Evaluation of HIV Transmission Clusters among Natives and Foreigners Living in Italy. <i>Viruses</i> , <b>2020</b> , 12,	6.2	5
204	Dolutegravir plus lamivudine for hiv treatment: Does the historical genotype really matter?. <i>EBioMedicine</i> , <b>2020</b> , 56, 102820	8.8	
203	Switching from boosted PIs to dolutegravir in HIV-infected patients with high cardiovascular risk: 48 week effects on subclinical cardiovascular disease. <i>Journal of Antimicrobial Chemotherapy</i> , <b>2020</b> , 75, 3334-3343	5.1	3
202	COVID-19: studying the global pandemic [foreword]. <i>Future Virology</i> , <b>2020</b> , 15, i-iv	2.4	1
201	Impact of NRTI resistance mutations on virological effectiveness of antiretroviral regimens containing elvitegravir: a multi-cohort study. <i>Journal of Antimicrobial Chemotherapy</i> , <b>2020</b> , 75, 194-199	5.1	0
200	A push for 90-90-90: Initial treatment with INSTI-based regimens against HIV-1 infection. <i>EClinicalMedicine</i> , <b>2019</b> , 13, 4-5	11.3	
199	Long-term data on the efficacy and tolerability of lamivudine plus dolutegravir as a switch strategy in a multi-centre cohort of HIV-1-infected, virologically suppressed patients. <i>International Journal of Antimicrobial Agents</i> , <b>2019</b> , 54, 728-734	14.3	21
198	A prospective randomized trial on abacavir/lamivudine plus darunavir/ritonavir or raltegravir in HIV-positive drug-naïve patients with CD4. <i>PLoS ONE</i> , <b>2019</b> , 14, e0222650	3.7	6
197	Effectiveness of dolutegravir-based regimens as either first-line or switch antiretroviral therapy: data from the Icona cohort. <i>Journal of the International AIDS Society</i> , <b>2019</b> , 22, e25227	5.4	24
196	Durability of first-line regimens including integrase strand transfer inhibitors (INSTIs): data from a real-life setting. <i>Journal of Antimicrobial Chemotherapy</i> , <b>2019</b> , 74, 1363-1367	5.1	17

195	Cardiovascular adverse events during treatment with darunavir-based regimens in an Italian observational study. <i>Drug Design, Development and Therapy</i> , <b>2019</b> , 13, 1667-1685	4.4	1
194	Impact of genotypic susceptibility score on cART outcomes during primary HIV infection. <i>Journal of Medical Virology</i> , <b>2019</b> , 91, 1891-1895	19.7	
193	Very high pre-therapy viral load is a predictor of virological rebound in HIV-1-infected patients starting a modern first-line regimen. <i>Antiviral Therapy</i> , <b>2019</b> , 24, 321-331	1.6	3
192	Is the rate of virological failure to cART continuing to decline in recent calendar years?. <i>Journal of Clinical Virology</i> , <b>2019</b> , 116, 23-28	14.5	3
191	Immediate Versus Deferred Switching From a Boosted Protease Inhibitor-based Regimen to a Dolutegravir-based Regimen in Virologically Suppressed Patients With High Cardiovascular Risk or Age 80 Years: Final 96-Week Results of the NEAT022 Study. <i>Clinical Infectious Diseases</i> , <b>2019</b> , 68, 597-606	11.6	18
190	Prevalence of acquired resistance mutations in a large cohort of perinatally infected HIV-1 patients. <i>Clinical Microbiology and Infection</i> , <b>2019</b> , 25, 1443-1446	9.5	6
189	Efficacy and safety of dolutegravir-based regimens in advanced HIV-infected naïve patients: results from a multicenter cohort study. <i>Antiviral Research</i> , <b>2019</b> , 169, 104552	10.8	13
188	Durability of INI-containing regimens after switching from PI-containing regimens: a single-centre cohort of drug-experienced HIV-infected subjects. <i>Drug Design, Development and Therapy</i> , <b>2019</b> , 13, 2271-2282	14.4	25
187	No impact of previous NRTIs resistance in HIV positive patients switched to DTG+2NRTIs under virological control: Time of viral suppression makes the difference. <i>Antiviral Research</i> , <b>2019</b> , 172, 104635	10.8	5
186	Cohort profile: The Observational cohort for the study of DOLutegravir in Antiretroviral Combination REGimens (ODOACRE). <i>BMJ Open</i> , <b>2019</b> , 9, e029960	3	7
185	The Effect of Switching to Maraviroc + Darunavir/Ritonavir Dual Therapy in Virologically Suppressed Patients on the Progression of Liver Fibrosis: Findings From a Randomized Study. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , <b>2019</b> , 81, e17-e21	3.1	2
184	Switch to dolutegravir and unboosted atazanavir in HIV-1 infected patients with undetectable viral load and long exposure to antiretroviral therapy. <i>Aids</i> , <b>2019</b> , 33, 1256-1260	3.5	8
183	Efficacy and safety of switching to dolutegravir plus emtricitabine/tenofovir disoproxil fumarate (TDF) or elvitegravir/cobicistat/emtricitabine/TDF in virologically suppressed HIV-infected patients in clinical practice: results from a multicentre, observational study. <i>HIV Medicine</i> , <b>2019</b> , 20, 164-168	2.7	18
182	Clinical pharmacology in HIV cure research - what impact have we seen?. <i>Expert Review of Clinical Pharmacology</i> , <b>2019</b> , 12, 17-29	3.8	3
181	Use of quantitative ultrasound as bone mineral density evaluation in an Italian female population living with HIV: A real-life experience. <i>Journal of Women and Aging</i> , <b>2019</b> , 31, 176-188	1.4	
180	A comparison between two dolutegravir-based two-drug regimens as switch strategies in a multicentre cohort of HIV-1-infected patients. <i>Antiviral Therapy</i> , <b>2019</b> , 24, 63-67	1.6	23
179	A prospective randomized trial on abacavir/lamivudine plus darunavir/ritonavir or raltegravir in HIV-positive drug-naïve patients with CD4 <b>2019</b> , 14, e0222650		
178	A prospective randomized trial on abacavir/lamivudine plus darunavir/ritonavir or raltegravir in HIV-positive drug-naïve patients with CD4 <b>2019</b> , 14, e0222650		

177	A prospective randomized trial on abacavir/lamivudine plus darunavir/ritonavir or raltegravir in HIV-positive drug-naïve patients with CD4 <b>2019</b> , 14, e0222650		
176	A prospective randomized trial on abacavir/lamivudine plus darunavir/ritonavir or raltegravir in HIV-positive drug-naïve patients with CD4 <b>2019</b> , 14, e0222650		
175	A Comprehensive Development Agenda on Tenofovir Alafenamide in Clinical Practice. <i>AIDS Reviews</i> , <b>2018</b> , 20, 75-82	1.5	2
174	Dolutegravir Plus Rilpivirine as a Switch Option in cART-Experienced Patients: 96-Week Data. <i>Annals of Pharmacotherapy</i> , <b>2018</b> , 52, 740-746	2.9	27
173	Efficacy and tolerability of lamivudine plus dolutegravir as a switch strategy in a multicentre cohort of patients with suppressed HIV-1 replication. <i>HIV Medicine</i> , <b>2018</b> , 19, 452	2.7	23
172	Dolutegravir (DTG)-containing regimens after receiving raltegravir (RAL) or elvitegravir (EVG): Durability and virological response in a large Italian HIV drug resistance network (ARCA). <i>Journal of Clinical Virology</i> , <b>2018</b> , 105, 112-117	14.5	9
171	Evolution of transmitted HIV-1 drug resistance and viral subtypes circulation in Italy from 2006 to 2016. <i>HIV Medicine</i> , <b>2018</b> , 19, 619-628	2.7	21
170	Switching to dual/monotherapy determines an increase in CD8+ in HIV-infected individuals: an observational cohort study. <i>BMC Medicine</i> , <b>2018</b> , 16, 79	11.4	16
169	Improvement of lipid profile after switching from efavirenz or ritonavir-boosted protease inhibitors to rilpivirine or once-daily integrase inhibitors: results from a large observational cohort study (SCOLTA). <i>BMC Infectious Diseases</i> , <b>2018</b> , 18, 357	4	21
168	Impact of social determinants on antiretroviral therapy access and outcomes entering the era of universal treatment for people living with HIV in Italy. <i>BMC Public Health</i> , <b>2018</b> , 18, 870	4.1	13
167	Survival in HIV-infected patients with lymphoma according to the choice of antiretroviral treatment: an observational multicentre study. <i>HIV Medicine</i> , <b>2018</b> , 19, 523	2.7	7
166	Impact of the M184V Resistance Mutation on Virological Efficacy and Durability of Lamivudine-Based Dual Antiretroviral Regimens as Maintenance Therapy in Individuals With Suppressed HIV-1 RNA: A Cohort Study. <i>Open Forum Infectious Diseases</i> , <b>2018</b> , 5, ofy113	1	34
165	Clinical and genetic determinants of nevirapine plasma trough concentration. <i>SAGE Open Medicine</i> , <b>2018</b> , 6, 2050312118780861	2.4	7
164	Long-term efficacy of dolutegravir in treatment-experienced subjects failing therapy with HIV-1 integrase strand inhibitor-resistant virus. <i>Journal of Antimicrobial Chemotherapy</i> , <b>2018</b> , 73, 177-182	5.1	18
163	Durability of dolutegravir plus boosted darunavir as salvage or simplification of salvage regimens in HIV-1 infected, highly treatment-experienced subjects. <i>HIV Clinical Trials</i> , <b>2018</b> , 19, 242-248		12
162	Clinical and genetic factors associated with increased risk of severe liver toxicity in a monocentric cohort of HIV positive patients receiving nevirapine-based antiretroviral therapy. <i>BMC Infectious Diseases</i> , <b>2018</b> , 18, 556	4	4
161	Pre-ART HIV-1 DNA in CD4+ T cells correlates with baseline viro-immunological status and outcome in patients under first-line ART. <i>Journal of Antimicrobial Chemotherapy</i> , <b>2018</b> , 73, 3460-3470	5.1	7
160	Correlation between inner retinal layer thickness and cognitive function in HIV: new insights from an exploratory study. <i>Aids</i> , <b>2018</b> , 32, 1485-1490	3.5	7



159	First-line antiretroviral therapy with efavirenz plus tenofovir disoproxil fumarate/emtricitabine or rilpivirine plus tenofovir disoproxil fumarate/emtricitabine: a durability comparison. <i>HIV Medicine</i> , <b>2018</b> , 19, 475	2.7	10
158	Atazanavir/ritonavir with lamivudine as maintenance therapy in virologically suppressed HIV-infected patients: 96 week outcomes of a randomized trial. <i>Journal of Antimicrobial Chemotherapy</i> , <b>2018</b> , 73, 1955-1964	5.1	20
157	Efficacy, safety and pharmacokinetics of atazanavir (200mg twice daily) plus raltegravir (400mg twice daily) dual regimen in the clinical setting. <i>Journal of Clinical Virology</i> , <b>2017</b> , 87, 30-36	14.5	5
156	Efficacy and tolerability of switching to a dual therapy with darunavir/ritonavir plus raltegravir in HIV-infected patients with HIV-1 RNA $\geq 10^4$ cp/mL. <i>Infection</i> , <b>2017</b> , 45, 521-528	5.8	9
155	The impact of adherence to HIV/AIDS antiretroviral therapy on the development of drug resistance. <i>Future Virology</i> , <b>2017</b> , 12, 239-241	2.4	4
154	Effect of Legal Status on the Early Treatment Outcomes of Migrants Beginning Combined Antiretroviral Therapy at an Outpatient Clinic in Milan, Italy. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , <b>2017</b> , 75, 315-321	3.1	9
153	Discontinuation of treatment and adverse events in an Italian cohort of patients on dolutegravir. <i>Aids</i> , <b>2017</b> , 31, 455-457	3.5	41
152	Incidence and progression to cirrhosis of new hepatitis C virus infections in persons living with human immunodeficiency virus. <i>Clinical Microbiology and Infection</i> , <b>2017</b> , 23, 267.e1-267.e4	9.5	7
151	Safety and tolerability of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Disoproxil fumarate in a real life setting: Data from surveillance cohort long-term toxicity antiretrovirals/antivirals (SCOLTA) project. <i>PLoS ONE</i> , <b>2017</b> , 12, e0179254	3.7	15
150	Projections of non-communicable disease and health care costs among HIV-positive persons in Italy and the U.S.A.: A modelling study. <i>PLoS ONE</i> , <b>2017</b> , 12, e0186638	3.7	40
149	Weight Gain: A Possible Side Effect of All Antiretrovirals. <i>Open Forum Infectious Diseases</i> , <b>2017</b> , 4, ofx239		55
148	A dual regimen of ritonavir/darunavir plus dolutegravir for rescue or simplification of rescue therapy: 48 weeks observational data. <i>BMC Infectious Diseases</i> , <b>2017</b> , 17, 658	4	37
147	Cardiovascular risk and dyslipidemia among persons living with HIV: a review. <i>BMC Infectious Diseases</i> , <b>2017</b> , 17, 551	4	71
146	Brief Report: Drop in CD4+ Counts Below 200 Cells/ $\mu$ L After Reaching (or Starting From) Values Higher than 350 Cells/ $\mu$ L in HIV-Infected Patients With Virological Suppression. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , <b>2017</b> , 76, 417-422	3.1	1
145	Efficacy and tolerability of dolutegravir and two nucleos(t)ide reverse transcriptase inhibitors in HIV-1-positive, virologically suppressed patients. <i>Aids</i> , <b>2017</b> , 31, 457-459	3.5	32
144	Durability of Second Antiretroviral Regimens in the Italian Cohort Naïve Antiretrovirals Foundation Study and Factors Associated with Discontinuation. <i>AIDS Patient Care and STDs</i> , <b>2017</b> , 31, 487-494	5.8	4
143	Active HCV Replication but Not HCV or CMV Seropositive Status Is Associated With Incident and Prevalent Type 2 Diabetes in Persons Living With HIV. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , <b>2017</b> , 75, 465-471	3.1	3
142	Clinical and genetic factors associated with kidney tubular dysfunction in a real-life single centre cohort of HIV-positive patients. <i>BMC Infectious Diseases</i> , <b>2017</b> , 17, 396	4	7

141	Switch to maraviroc with darunavir/r, both QD, in patients with suppressed HIV-1 was well tolerated but virologically inferior to standard antiretroviral therapy: 48-week results of a randomized trial. <i>PLoS ONE</i> , <b>2017</b> , 12, e0187393	3.7	9
140	Proportion and factors associated with recent HIV infection in a cohort of patients seen for care in Italy over 1996-2014: Data from the ICONA Foundation Study cohort. <i>PLoS ONE</i> , <b>2017</b> , 12, e0189045	3.7	4
139	Novelties in evaluation and monitoring of HIV-1 infection: Is standard virological suppression enough for measuring antiretroviral treatment success?. <i>AIDS Reviews</i> , <b>2017</b> , 19,	1.5	3
138	Treatment simplification to atazanavir/ritonavir + lamivudine versus maintenance of atazanavir/ritonavir + two NRTIs in virologically suppressed HIV-1-infected patients: 48 week results from a randomized trial (ATLAS-M). <i>Journal of Antimicrobial Chemotherapy</i> , <b>2017</b> , 72, 1163-1171	5.1	56
137	Salvage therapy or simplification of salvage regimens with dolutegravir plus ritonavir-boosted darunavir dual therapy in highly cART-experienced subjects: an Italian cohort. <i>Antiviral Therapy</i> , <b>2017</b> , 22, 257-262	1.6	15
136	Impact of circulating resistance-associated mutations on HIV pre-exposure prophylaxis (PrEP) efficacy: Modeling from antiretroviral resistance cohort analysis (ARCA) national database. <i>Journal of Clinical Virology</i> , <b>2016</b> , 83, 48-53	14.5	2
135	Triglyceride/HDL ratio and its impact on the risk of diabetes mellitus development during ART. <i>Journal of Antimicrobial Chemotherapy</i> , <b>2016</b> , 71, 2663-9	5.1	9
134	Relapse of Kaposi's Sarcoma and HHV-8 viremia in an HIV-infected patient switching from protease inhibitor to integrase inhibitor-based antiretroviral therapy. <i>Journal of Clinical Virology</i> , <b>2016</b> , 74, 75-7	14.5	10
133	Atazanavir/ritonavir monotherapy: 96 week efficacy, safety and bone mineral density from the MODAt randomized trial. <i>Journal of Antimicrobial Chemotherapy</i> , <b>2016</b> , 71, 1637-42	5.1	5
132	Integrase inhibitors against HIV: efficacy and resistance. <i>Future Virology</i> , <b>2016</b> , 11, 109-112	2.4	
131	Increased risk of virologic failure to the first antiretroviral regimen in HIV-infected migrants compared to natives: data from the ICONA cohort. <i>Clinical Microbiology and Infection</i> , <b>2016</b> , 22, 288.e1-8	9.5	27
130	Long-Term Durability of Tenofovir-Based Antiretroviral Therapy in Relation to the Co-Administration of Other Drug Classes in Routine Clinical Practice. <i>PLoS ONE</i> , <b>2016</b> , 11, e0160761	3.7	4
129	Response to First-Line Ritonavir-Boosted Protease Inhibitors (PI/r)-Based Regimens in HIV Positive Patients Presenting to Care with Low CD4 Counts: Data from the Icona Foundation Cohort. <i>PLoS ONE</i> , <b>2016</b> , 11, e0156360	3.7	
128	Effectiveness, durability, and safety of darunavir/ritonavir in HIV-1-infected patients in routine clinical practice in Italy: a postauthorization noninterventional study. <i>Drug Design, Development and Therapy</i> , <b>2016</b> , 10, 1589-603	4.4	5
127	Discontinuation of Initial Antiretroviral Therapy in Clinical Practice: Moving Toward Individualized Therapy. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , <b>2016</b> , 71, 263-71	3.1	33
126	European AIDS Clinical Society Standard of Care meeting on HIV and related coinfections: The Rome Statements. <i>HIV Medicine</i> , <b>2016</b> , 17, 445-52	2.7	6
125	Factors involved in continuance of atazanavir-based regimens: Results from a cohort of HIV1-positive patients. <i>Antiviral Research</i> , <b>2016</b> , 129, 52-57	10.8	2
124	Development and validation of a risk score for chronic kidney disease in HIV infection using prospective cohort data from the D:A:D study. <i>PLoS Medicine</i> , <b>2015</b> , 12, e1001809	11.6	107



123	Successful pharmacogenetics-based optimization of unboosted atazanavir plasma exposure in HIV-positive patients: a randomized, controlled, pilot study (the REYAGEN study). <i>Journal of Antimicrobial Chemotherapy</i> , <b>2015</b> , 70, 3096-9	5.1	14
122	Cytomegalovirus coinfection is associated with an increased risk of severe non-AIDS-defining events in a large cohort of HIV-infected patients. <i>Journal of Infectious Diseases</i> , <b>2015</b> , 211, 178-86	7	114
121	Incidence and factors associated with the risk of sexually transmitted diseases in HIV-infected people seen for care in Italy: data from the Icona Foundation cohort. <i>HIV Medicine</i> , <b>2015</b> , 16, 412-20	2.7	2
120	Evaluation of the Prognostic Value of Impaired Renal Function on Clinical Progression in a Large Cohort of HIV-Infected People Seen for Care in Italy. <i>PLoS ONE</i> , <b>2015</b> , 10, e0124252	3.7	5
119	Prognostic Value of the Fibrosis-4 Index in Human Immunodeficiency Virus Type-1 Infected Patients Initiating Antiretroviral Therapy with or without Hepatitis C Virus. <i>PLoS ONE</i> , <b>2015</b> , 10, e0140877	3.7	7
118	Circulating microRNAs in Sera Correlate with Soluble Biomarkers of Immune Activation but Do Not Predict Mortality in ART Treated Individuals with HIV-1 Infection: A Case Control Study. <i>PLoS ONE</i> , <b>2015</b> , 10, e0139981	3.7	8
117	CD4/CD8 ratio normalisation and non-AIDS-related events in individuals with HIV who achieve viral load suppression with antiretroviral therapy: an observational cohort study. <i>Lancet HIV</i> , <b>2015</b> , 2, e98-106	7.8	172
116	State of the Art of Dual Therapy in 2015. <i>AIDS Reviews</i> , <b>2015</b> , 17, 127-34	1.5	6
115	An update on integrase inhibitors: new opportunities for a personalized therapy? The NEXTaim Project. <i>New Microbiologica</i> , <b>2015</b> , 38, 443-90	1.1	6
114	Longitudinal analysis of HIV-1 coreceptor tropism by single and triplicate HIV-1 RNA and DNA sequencing in patients undergoing successful first-line antiretroviral therapy. <i>Journal of Antimicrobial Chemotherapy</i> , <b>2014</b> , 69, 735-41	5.1	15
113	Atazanavir/ritonavir monotherapy as maintenance strategy in HIV-1 treated subjects with viral suppression: 96-week analysis results of the MODAT study. <i>Journal of the International AIDS Society</i> , <b>2014</b> , 17, 19806	5.4	4
112	Safety and therapeutic efficacy of the switch to maraviroc+darunavir/ritonavir in HIV/HCV coinfectd patients: initial results from GUSTA study. <i>Journal of the International AIDS Society</i> , <b>2014</b> , 17, 19818	5.4	8
111	Treatment outcome in HIV+ patients receiving 3- or 4-drug regimens during PHI. <i>Journal of the International AIDS Society</i> , <b>2014</b> , 17, 19778	5.4	4
110	Simplification to atazanavir/ritonavir+lamivudine in virologically suppressed HIV-infected patients: 24-weeks interim analysis from ATLAS-M trial. <i>Journal of the International AIDS Society</i> , <b>2014</b> , 17, 19808	5.4	13
109	Factors involved in treatment durability and immunological recovery in a cohort of HIV-positive patients receiving atazanavir-based regimens. <i>Journal of the International AIDS Society</i> , <b>2014</b> , 17, 19830	5.4	
108	The problem of renal function monitoring in patients treated with the novel antiretroviral drugs. <i>HIV Clinical Trials</i> , <b>2014</b> , 15, 87-91		9
107	Genotypic determination of HIV tropism in a cohort of patients perinatally infected with HIV-1 and exposed to antiretroviral therapy. <i>HIV Clinical Trials</i> , <b>2014</b> , 15, 45-50		7
106	The role of baseline HIV-1 RNA, drug resistance, and regimen type as determinants of response to first-line antiretroviral therapy. <i>Journal of Medical Virology</i> , <b>2014</b> , 86, 1648-55	19.7	15

105	Rilpivirine resistance and the dangerous liaisons with substitutions at position 184 among patients infected with HIV-1: analysis from a national drug-resistance database (ARCA). <i>Journal of Medical Virology</i> , <b>2014</b> , 86, 1459-66	19.7	2
104	Evolution of HIV-1 tropism at quasispecies level after 5 years of combination antiretroviral therapy in patients always suppressed or experiencing episodes of virological failure. <i>Journal of Antimicrobial Chemotherapy</i> , <b>2014</b> , 69, 3085-94	5.1	6
103	Favorable therapeutic response with an antiretroviral salvage regimen in an HIV-1-positive subject infected with a CRF11-cpx virus. <i>AIDS Research and Human Retroviruses</i> , <b>2014</b> , 30, 480-3	1.6	
102	Simplification to atazanavir/ritonavir monotherapy for HIV-1 treated individuals on virological suppression: 48-week efficacy and safety results. <i>Aids</i> , <b>2014</b> , 28, 2269-79	3.5	19
101	Clinical and epidemiological features of HIV/AIDS infection among migrants at first access to healthcare services as compared to Italian patients in Italy: a retrospective multicentre study, 2000-2010. <i>Infection</i> , <b>2014</b> , 42, 859-67	5.8	15
100	Novel antiretroviral drugs and renal function monitoring of HIV patients. <i>AIDS Reviews</i> , <b>2014</b> , 16, 144-51	1.5	29
99	Prevalence of etravirine (ETR)-RAMs at NNRTI failure and predictors of resistance to ETR in a large Italian resistance database (ARCA). <i>Clinical Microbiology and Infection</i> , <b>2013</b> , 19, E443-6	9.5	1
98	Factors associated with virological success with raltegravir-containing regimens and prevalence of raltegravir-resistance-associated mutations at failure in the ARCA database. <i>Clinical Microbiology and Infection</i> , <b>2013</b> , 19, 936-42	9.5	9
97	Symmetric ambulatory arterial stiffness index and 24-h pulse pressure in HIV infection: results of a nationwide cross-sectional study. <i>Journal of Hypertension</i> , <b>2013</b> , 31, 560-7; discussion 567	1.9	17
96	Maraviroc as intensification strategy in HIV-1 positive patients with deficient immunological response: an Italian randomized clinical trial. <i>PLoS ONE</i> , <b>2013</b> , 8, e80157	3.7	31
95	Cross-sectional study of community serostatus to highlight undiagnosed HIV infections with oral fluid HIV-1/2 rapid test in non-conventional settings. <i>New Microbiologica</i> , <b>2013</b> , 36, 121-32	1.1	7
94	Efficacy and safety of rilpivirine in treatment-naïve, HIV-1-infected patients with hepatitis B virus/hepatitis C virus coinfection enrolled in the Phase III randomized, double-blind ECHO and THRIVE trials. <i>Journal of Antimicrobial Chemotherapy</i> , <b>2012</b> , 67, 2020-8	5.1	27
93	Efficacy and safety of a dual boosted protease inhibitor-based regimen, atazanavir and fosamprenavir/ritonavir, against HIV: experience in a pediatric population. <i>BMC Infectious Diseases</i> , <b>2012</b> , 12, 179	4	3
92	The feature of Metabolic Syndrome in HIV naïve patients is not the same of those treated: results from a prospective study. <i>Biomedicine and Pharmacotherapy</i> , <b>2012</b> , 66, 348-53	7.5	19
91	Low frequency of skin reactions in a cohort of patients on raltegravir. <i>Journal of Antimicrobial Chemotherapy</i> , <b>2012</b> , 67, 1800-2	5.1	1
90	Immunological nonresponse to antiretroviral drugs in HIV infection. <i>Future Virology</i> , <b>2012</b> , 7, 1145-1147	2.4	
89	Renal complications in HIV disease: between present and future. <i>AIDS Reviews</i> , <b>2012</b> , 14, 37-53	1.5	24
88	The Less Drugs Regimens (LDRs) therapy approach in HIV-1: an Italian expert panel perspective for the long-term management of HIV-1 infection. <i>New Microbiologica</i> , <b>2012</b> , 35, 259-77	1.1	5

87	Tipranavir in the protease inhibitors arena. <i>Drugs in R and D</i> , <b>2011</b> , 11, 291-3	3.4	2
86	A novel methodology for large-scale phylogeny partition. <i>Nature Communications</i> , <b>2011</b> , 2, 321	17.4	93
85	Investigators involvement in the care of HIV-infected individuals: the experience in recent clinical trials. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , <b>2011</b> , 58, e118-9	3.1	3
84	Does GSS still maintain relevance on HAART outcome after the introduction of newest active antiretroviral drugs? 48 weeks results. <i>Current HIV Research</i> , <b>2011</b> , 9, 625-9	1.3	2
83	Efficacy and safety of a switch to unboosted atazanavir in combination with nucleoside analogues in HIV-1-infected patients with virological suppression under antiretroviral therapy. <i>Journal of Antimicrobial Chemotherapy</i> , <b>2011</b> , 66, 2372-8	5.1	28
82	Comparative evaluation of seven resistance interpretation algorithms and their derived genotypic inhibitory quotients for the prediction of 48 week virological response to darunavir-based salvage regimens. <i>Journal of Antimicrobial Chemotherapy</i> , <b>2011</b> , 66, 192-200	5.1	14
81	Effects of intermittent IL-2 alone or with peri-cycle antiretroviral therapy in early HIV infection: the STALWART study. <i>PLoS ONE</i> , <b>2010</b> , 5, e9334	3.7	16
80	Therapeutic immunization with HIV-1 Tat reduces immune activation and loss of regulatory T-cells and improves immune function in subjects on HAART. <i>PLoS ONE</i> , <b>2010</b> , 5, e13540	3.7	73
79	Prevalence and risk determinants of HIV-1 and HIV-2 infections in pregnant women in Bissau. <i>Journal of Infection</i> , <b>2010</b> , 61, 391-8	18.9	9
78	Prevalence of mutations and determinants of genotypic resistance to etravirine (TMC125) in a large Italian resistance database (ARCA). <i>HIV Medicine</i> , <b>2010</b> , 11, 530-4	2.7	6
77	New macrocyclic amines showing activity as HIV entry inhibitors against wild type and multi-drug resistant viruses. <i>Molecules</i> , <b>2009</b> , 14, 1927-37	4.8	5
76	Efficacy and resistance of recently developed non-nucleoside reverse transcriptase inhibitors for HIV-1. <i>HIV Therapy</i> , <b>2009</b> , 3, 63-77		5
75	Tipranavir: a novel protease inhibitor for HIV therapy. <i>Expert Review of Clinical Pharmacology</i> , <b>2009</b> , 2, 147-53	3.8	1
74	Rules-based HIV-1 genotypic resistance interpretation systems predict 8 week and 24 week virological antiretroviral treatment outcome and benefit from drug potency weighting. <i>Journal of Antimicrobial Chemotherapy</i> , <b>2009</b> , 64, 616-24	5.1	33
73	Italian consensus statement on management of HIV-infected individuals with advanced disease naïve to antiretroviral therapy. <i>Infection</i> , <b>2009</b> , 37, 270-82	5.8	7
72	Clinical validation and applicability of different tipranavir/ritonavir genotypic scores in HIV-1 protease inhibitor-experienced patients. <i>Current HIV Research</i> , <b>2009</b> , 7, 425-33	1.3	1
71	Evolution of the HIV-1 protease region in heavily pretreated HIV-1 infected patients receiving Atazanavir. <i>Journal of Clinical Virology</i> , <b>2008</b> , 41, 154-9	14.5	3
70	Update on the development of HIV entry inhibitors. <i>Future HIV Therapy</i> , <b>2008</b> , 2, 479-507		2

69	Successful rescue therapy with Raltegravir (MK-0518) and Etravirine (TMC125) in an hiv-infected patient failing all four classes of antiretroviral drugs. <i>AIDS Patient Care and STDs</i> , <b>2008</b> , 22, 355-7	5.8	9
68	Description of a "trans-Saharan" strain of human T-lymphotropic virus type 1 in West Africa. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , <b>2008</b> , 47, 269-73	3.1	14
67	Phosph(on)ate as a zinc-binding group in metalloenzyme inhibitors: X-ray crystal structure of the antiviral drug foscarnet complexed to human carbonic anhydrase I. <i>Bioorganic and Medicinal Chemistry Letters</i> , <b>2007</b> , 17, 2210-5	2.9	45
66	Inhibitors of HIV-1 protease: current state of the art 10 years after their introduction. From antiretroviral drugs to antifungal, antibacterial and antitumor agents based on aspartic protease inhibitors. <i>Current Medicinal Chemistry</i> , <b>2007</b> , 14, 2734-48	4.3	115
65	An update in the development of HIV entry inhibitors. <i>Current Topics in Medicinal Chemistry</i> , <b>2007</b> , 7, 1273-89	3	56
64	Combined tipranavir and enfuvirtide use associated with higher plasma tipranavir concentrations but not with increased hepatotoxicity: sub-analysis from RESIST. <i>Aids</i> , <b>2007</b> , 21, 1977-80	3.5	16
63	Safety of statin therapy in HIV/hepatitis C virus-coinfected patients. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , <b>2007</b> , 46, 258-60	3.1	10
62	Novel inhibitors of the early steps of the HIV-1 life cycle. <i>Expert Opinion on Investigational Drugs</i> , <b>2007</b> , 16, 11-23	5.9	7
61	Abacavir hypersensitivity reaction after switching from the twice-daily to the once-daily formulation. <i>AIDS Patient Care and STDs</i> , <b>2007</b> , 21, 1-3	5.8	16
60	Treatment response to ritonavir-boosted tipranavir versus ritonavir-boosted lopinavir in HIV-1 patients with higher lopinavir mutation scores. <i>Aids</i> , <b>2007</b> , 21, 2245-8	3.5	6
59	Determinants of HIV-1 genotypic resistance to darunavir (TMC114) in a large Italian resistance database (Antiretroviral Resistance Cohort Analysis). <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , <b>2007</b> , 46, 373-5	3.1	1
58	11th European AIDS Conference, Madrid, Spain, 24-27 October 2007. <i>Journal of HIV Therapy</i> , <b>2007</b> , 12, 102-4		
57	Inhibitors of HIV-1 protease: 10 years after. <i>Expert Opinion on Therapeutic Patents</i> , <b>2006</b> , 16, 1067-1091	6.8	18
56	Failure to eradicate HIV despite fully successful HAART initiated in the first days of life. <i>Journal of Pediatrics</i> , <b>2006</b> , 148, 389-91	3.6	22
55	Vpr and HIV-1 disease progression: R77Q mutation is associated with long-term control of HIV-1 infection in different groups of patients. <i>Aids</i> , <b>2006</b> , 20, 567-74	3.5	49
54	New HIV protease inhibitors for drug-resistant viruses. <i>Therapy: Open Access in Clinical Medicine</i> , <b>2006</b> , 3, 79-88		
53	Revisiting the concept of a genetic barrier to resistance. <i>Journal of HIV Therapy</i> , <b>2006</b> , 11, 81-3		1
52	Absence of new thymidine-associated mutations and evidence of an immune virologic response over a 12-month period in a cohort of antiretroviral-experienced HIV-1-infected subjects treated with tenofovir combination therapy. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , <b>2005</b> , 40, 238-41	3.1	

51	Efficacy and tolerability of multiple drug therapy in HIV-infected children. <i>Journal of Infection</i> , <b>2005</b> , 50, 404-11	18.9	3
50	Analysis of the env V3 sequences obtained from patients with HIV type 1 infection treated with the immune modulant agent tucareol. <i>AIDS Research and Human Retroviruses</i> , <b>2005</b> , 21, 815-9	1.6	1
49	Human cytomegalovirus double resistance in a donor-positive/recipient-negative lung transplant patient with an impaired CD4-mediated specific immune response. <i>Journal of Antimicrobial Chemotherapy</i> , <b>2004</b> , 53, 536-9	5.1	18
48	Entry and fusion inhibitors of HIV. <i>Expert Opinion on Therapeutic Patents</i> , <b>2004</b> , 14, 733-748	6.8	4
47	Analysis of protease inhibitor combinations in vitro: activity of lopinavir, amprenavir and tipranavir against HIV type 1 wild-type and drug-resistant isolates. <i>Journal of Antimicrobial Chemotherapy</i> , <b>2004</b> , 53, 464-8	5.1	16
46	Carbonic anhydrase inhibitors. Interaction of isozymes I, II, IV, V, and IX with phosphates, carbamoyl phosphate, and the phosphonate antiviral drug foscarnet. <i>Bioorganic and Medicinal Chemistry Letters</i> , <b>2004</b> , 14, 5763-7	2.9	23
45	Unusual codon 69 insertions: influence on human immunodeficiency virus type 1 reverse transcriptase drug susceptibility. <i>Journal of Clinical Virology</i> , <b>2004</b> , 29, 27-32	14.5	10
44	New advances in HIV entry inhibitors development. <i>Current Drug Targets Infectious Disorders</i> , <b>2004</b> , 4, 339-55		31
43	Processivity and drug-dependence of HIV-1 protease. <i>Aids</i> , <b>2003</b> , 17, 663-671	3.5	24
42	Declining incidence of AIDS and increasing prevalence of AIDS presenters among AIDS patients in Italy. <i>European Journal of Clinical Microbiology and Infectious Diseases</i> , <b>2003</b> , 22, 663-9	5.3	19
41	Tipranavir. <i>Drugs</i> , <b>2003</b> , 63, 1619-20	12.1	
40	Immunovirological outcomes in 70 HIV-1-infected patients who switched to lopinavir/ritonavir after failing at least one protease inhibitor-containing regimen: a retrospective cohort study. <i>Journal of Antimicrobial Chemotherapy</i> , <b>2003</b> , 51, 171-4	5.1	5
39	Natural History of HIV Infection <b>2003</b> , 35-46		
38	Low expression of inhibitory natural killer receptors in CD8 cytotoxic T lymphocytes in long-term non-progressor HIV-1-infected patients. <i>Aids</i> , <b>2003</b> , 17, 257-60	3.5	13
37	Virological Success of Lopinavir/Ritonavir Salvage Regimen is Affected by an Increasing Number of Lopinavir/Ritonavir-Related Mutations. <i>Antiviral Therapy</i> , <b>2003</b> , 8, 209-214	1.6	10
36	Simplification of Protease Inhibitor-Containing Regimens with Efavirenz, Nevirapine or Abacavir: Safety and Efficacy Outcomes. <i>Antiviral Therapy</i> , <b>2003</b> , 8, 27-35	1.6	9
35	HIV-1 protease inhibitors in development. <i>Expert Opinion on Investigational Drugs</i> , <b>2002</b> , 11, 387-95	5.9	12
34	Accumulation of drug-related mutations in HIV-1 genome and virus replicative capacity in multi-drug failure subjects. <i>Journal of Antimicrobial Chemotherapy</i> , <b>2002</b> , 49, 427-9	5.1	

33	In vitro evolution of the human immunodeficiency virus type 1 gag-protease region and maintenance of reverse transcriptase resistance following prolonged drug exposure. <i>Journal of Clinical Microbiology</i> , <b>2001</b> , 39, 1124-9	9.7	11
32	Predictive role of the three-month CD4 cell count in the long-term clinical outcome of the first HAART regimen. <i>Biomedicine and Pharmacotherapy</i> , <b>2001</b> , 55, 16-22	7.5	2
31	Differential disappearance of inhibitory natural killer cell receptors during HAART and possible impairment of HIV-1-specific CD8 cytotoxic T lymphocytes. <i>Aids</i> , <b>2001</b> , 15, 965-74	3.5	37
30	Virological Response in Multidrug-Experienced HIV-1-Infected Subjects Failing Highly Active Combination Regimens after Shifting from Lamivudine to Didanosine. <i>Antiviral Therapy</i> , <b>2001</b> , 6, 41-46	1.6	4
29	Quantitative evaluation of the recombinant HIV-1 phenotype to protease inhibitors by a single-step strategy. <i>Aids</i> , <b>2000</b> , 14, 1101-10	3.5	9
28	Susceptibility to PNU-140690 (Tipranavir) of human immunodeficiency virus type 1 isolates derived from patients with multidrug resistance to other protease inhibitors. <i>Antimicrobial Agents and Chemotherapy</i> , <b>2000</b> , 44, 1328-32	5.9	88
27	Response to antiretroviral therapy in a patient with an uncommon codon 69 insertion in the human immunodeficiency virus type 1 reverse transcriptase. <i>Antimicrobial Agents and Chemotherapy</i> , <b>2000</b> , 44, 1767	5.9	4
26	Combination of CCR5 and CXCR4 inhibitors in therapy of human immunodeficiency virus type 1 infection: in vitro studies of mixed virus infections. <i>Journal of Virology</i> , <b>2000</b> , 74, 9328-32	6.6	28
25	A genotypic analysis of patients receiving Zidovudine with either Lamivudine, Didanosine or Zalcitabine dual therapy using the LiPA point mutation assay to detect genotypic variation at codons 41, 69, 70, 74, 184 and 215. <i>Journal of Clinical Virology</i> , <b>2000</b> , 19, 135-42	14.5	11
24	Clinical impact of anti retroviral resistance testing: current problems and future directions. <i>International Journal of Antimicrobial Agents</i> , <b>2000</b> , 16, 425-7	14.3	1
23	In Vitro Inhibition of HIV-1 by Met-Sdf-1 Alone or in Combination with Antiretroviral Drugs. <i>Antiviral Therapy</i> , <b>2000</b> , 5, 199-204	1.6	1
22	Prevalence of Transmitted Nucleoside Analogue-Resistant HIV-1 Strains and Pre-Existing Mutations in Pol Reverse Transcriptase and Protease Region: Outcome after Treatment in Recently Infected Individuals. <i>Antiviral Therapy</i> , <b>2000</b> , 5, 7-14	1.6	21
21	Persisting HIV-1 Replication Triggered by Acute Hepatitis a Virus Infection. <i>Antiviral Therapy</i> , <b>2000</b> , 5, 15-17	1.6	10
20	Evidence of stavudine-related phenotypic resistance among zidovudine-pretreated HIV-1-infected subjects receiving a therapeutic regimen of stavudine plus lamivudine. <i>Journal of Acquired Immune Deficiency Syndromes</i> , <b>1999</b> , 22, 101-3		9
19	Aminooxypentane-RANTES, an inhibitor of R5 human immunodeficiency virus type 1, increases the interferon gamma to interleukin 10 ratio without impairing cellular proliferation. <i>AIDS Research and Human Retroviruses</i> , <b>1999</b> , 15, 861-7	1.6	5
18	Altered signaling lymphocytic activation molecule (SLAM) expression in HIV infection and redirection of HIV-specific responses via SLAM triggering. <i>Clinical Immunology</i> , <b>1999</b> , 92, 276-84	9	9
17	CD4 cell counts at the third month of HAART may predict clinical failure. <i>Aids</i> , <b>1999</b> , 13, 1669-76	3.5	43
16	Effective inhibition of HIV-1 isolated from patients with acute primary HIV-1 infection by aminooxypentane-RANTES. <i>Aids</i> , <b>1999</b> , 13, 1144-5	3.5	4



15	Expression of CD38 on CD8 T cells predicts maintenance of high viraemia in HAART-treated HIV-1-infected children. Highly active antiretroviral therapy. <i>Lancet, The</i> , <b>1998</b> , 352, 1905-6	40	38
14	Lack of in vitro anti-gp160 antibody production is a correlate of nonprogression among HIV type 1-infected individuals. <i>AIDS Research and Human Retroviruses</i> , <b>1998</b> , 14, 1341-3	1.6	3
13	Clinical outcome and predictive factors of failure of highly active antiretroviral therapy in antiretroviral-experienced patients in advanced stages of HIV-1 infection. <i>Aids</i> , <b>1998</b> , 12, 1631-7	3.5	110
12	Cutaneous infection caused by <i>Mycobacterium gordonae</i> in a human immunodeficiency virus-infected patient receiving antimycobacterial treatment. <i>Clinical Infectious Diseases</i> , <b>1997</b> , 25, 1490-1	11.6	14
11	Patterns of in vitro anti-human immunodeficiency virus type 1 antibody production in long-term nonprogressors. <i>Clinical Immunology and Immunopathology</i> , <b>1997</b> , 85, 320-3		4
10	Use of multiplex PCR assay and DNA fingerprinting analysis for typing of multidrug-resistant <i>Mycobacterium tuberculosis</i> strains. <i>Journal of Infection</i> , <b>1997</b> , 35, 322-3	18.9	
9	Serious heart involvement with central nervous system impairment in bilateral pneumonia due to <i>Mycoplasma pneumoniae</i> . <i>Clinical Microbiology Newsletter</i> , <b>1996</b> , 18, 182-183	1.1	
8	No evidence of a higher risk of progression to AIDS in patients with HIV-1-related severe thrombocytopenia. <i>Journal of Acquired Immune Deficiency Syndromes</i> , <b>1996</b> , 12, 268-75		9
7	Reversible diabetes in patient with AIDS-related Kaposi's sarcoma treated with interferon alpha-2a. <i>Lancet, The</i> , <b>1995</b> , 345, 1438-9	40	20
6	Serum 2'5'-oligoadenylate synthetase levels and clinical response to interferon-beta therapy in women with genital human papillomavirus infection. <i>Journal of Infectious Diseases</i> , <b>1994</b> , 169, 1112-5	7	12
5	Inhibition of human immunodeficiency virus type 1 replication in cytokine-stimulated monocytes/macrophages by combination therapy. <i>Journal of Infectious Diseases</i> , <b>1994</b> , 170, 1361-6	7	19
4	Tracheoesophageal fistula in an HIV-1-positive man due to dual infection of <i>Candida albicans</i> and cytomegalovirus. <i>Chest</i> , <b>1994</b> , 106, 284-5	5.3	16
3	Correlation between continuous Positive end-expiratory pressure (PEEP) values and occurrence of Pneumothorax and Pneumomediastinum in SARS-CoV2 patients during non-invasive ventilation with Helmet		3
2	Self-Reported Symptoms of SARS-CoV-2 Infection in a Nonhospitalized Population in Italy: Cross-Sectional Study of the EPICOV19 Web-Based Survey (Preprint)		1
1	Association of Toll-like receptor 7 variants with life-threatening COVID-19 disease in males		2